DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Otros (Other)
Lipid Nanocarriers for Oligonucleotide Delivery to the Brain
This chapter reviews recent developments in the use of synthetic oligonucleotides to control gene expression in neuronal cells and the potential formulations to reach the brain. Brain pathologies affect a large number of individuals and have devastating repercussions in global health. The population ageing is expected to increase the incidence of brain diseases in the forthcoming years. One of the most exciting nucleic acid-based therapeutics used for downregulating gene expression is the antisense oligonucleotides. The application of these chimeras has proven to be also valuable in the treatment, diagnosis and imaging of brain tumours. Lipid spherical vesicles, such as liposomes, were first introduced in 1965, and since then they have been at the forefront of drug delivery science. Niosomes are another important class of vesicular systems similar to liposomes in which the phospholipids are substituted by non-ionic surfactants., The authors acknowledge the financial support provided by CIBER-BBN an
initiative funded by the VI National R+D+I Plan 2008–2011, Iniciativa
Ingenio 2010, Consolider Program and The Instituto de Salud Carlos III with
assistance from the European Regional Development and ICTS NANBIOSIS
(Oligonucleotide synthesis platform U29). IQAC group is supported by the
Spanish Ministerio de Ciencia e Innovación (CTQ2017-84415-R) and
Generalitat de Catalunya (2017SGR114). CQC is supported by FCT through
the projects Pest-OE-QUI/UI0313/2014 and POCI-01-0145-FEDER-007630.
A.F.J. acknowledges Fundação para a Ciência e Tecnologia (FCT), Portugal,
for financial support regarding Post-Doctoral grant SFRH/BPD/104544/2014., Peer reviewed